Methylprednisolone in adults hospitalized with COVID-19 pneumonia : An open-label randomized trial (GLUCOCOVID).

PURPOSE: To determine whether a 6-day course of methylprednisolone (MP) improves outcome in patients with severe SARS-CoV­2 (Corona Virus Disease 2019 [COVID-19]). METHODS: The study was a multicentric open-label trial of COVID-19 patients who were aged ≥ 18 years, receiving oxygen without mechanical ventilation, and with evidence of systemic inflammatory response who were assigned to standard of care (SOC) or SOC plus intravenous MP (40 mg bid for 3 days followed by 20 mg bid for 3 days). The primary outcome was a composite of death, admission to the intensive care unit, or requirement for noninvasive ventilation. Both intention-to-treat (ITT) and per protocol (PP) analyses were performed. RESULTS: A total of 91 patients were screened, and 64 were randomized (mean age70 ± 12 years). In the ITT analysis, 14 of 29 patients (48%) in the SOC group and 14 of 35 (40%) in the MP group suffered the composite endpoint (40% versus 20% in patients under 72 years and 67% versus 48% in those over 72 years; p = 0.25). In the PP analysis, patients on MP had a significantly lower risk of experiencing the composite endpoint (age-adjusted risk ratio 0.42; 95% confidence interval, CI 0.20-0.89; p = 0.043). CONCLUSION: The planned sample size was not achieved, and our results should therefore be interpreted with caution. The use of MP had no significant effect on the primary endpoint in ITT analysis; however, the PP analysis showed a beneficial effect due to MP, which consistent with other published trials support the use of glucocorticoids in severe cases of COVID-19.

Monitoring dihydrodiol polyaromatic hydrocarbon metabolites produced by the freshwater microalgae Selenastrum capricornutum.

We found that microalgae exposed to a mixture of polycyclic aromatic hydrocarbons (PAHs) did not show growth inhibition. Thus, we assumed that they could metabolize these compounds. In this study, the dihydrodiol-type PAH metabolites of benzo(a)pyrene (BaP), benzo(a)anthracene (BaA), benzo(b)fluoranthene (BbF) and benzo(k)fluoranthene (BkF) produced by the freshwater microalgae Selenastrum capricornutum were monitored and quantified using high-performance liquid chromatography with fluorescence detection (HPLC-FD) techniques. Exposure bioassays with S. capricornutum were performed using a 266 ng mL(-1) mixture of PAHs at different exposure times (0.75, 1, 3, 8, 16, 24 and 48 h) under controlled temperature (25 °C); the dihydrodiol metabolites formed in the liquid medium and the biomass were quantified. Metabolite identities were confirmed using HPLC-mass spectrometry; most of the metabolites formed were derived from BaA degradation. At 48 h after exposure 5,6-dBaA and 8,9-dBaA/10,11-dBaA were present in the liquid medium at 20% and 67% of the initial mass of BaA, respectively. Three metabolites of BaP were monitored in the liquid medium and biomass and, at 24 h, 4,5-dBaP accounted for 19%; , 7,8-dBaP, 5%; and 9,10-dBaP, 5% relative to the initial BaP mass. Microalgae exposed to BbF showed the presence of 1,2-dBbF and 9,10-dBbF (at 0.3% and 0.1% of the initial BbF mass, respectively) and those exposed to BkF produced 8,9-dBkF (6.5% of the initial BkF mass) in the liquid medium. Seven unknown compounds were formed after exposure; two compounds were identified as the metabolites of BaA and BaP. The results could facilitate the elucidation of the controversial biodegradation mechanism in microalgae.